Purpose of review Current regimens of combination antiretroviral therapy (cART) offer effective control of HIV infection, with maintenance of immune health and near-normal life expectancy. What will it take to progress beyond the status quo, whereby infectious virus can be eradicated (a 'sterilizing cure') or fully controlled without the need for ongoing cART (a 'functional cure')?
INTRODUCTION
Once dismissed as a mere pipe dream, the quest for a cure of HIV infection has moved with cautious optimism toward the forefront of HIV treatment research (reviewed in [1] [2] [3] [4] ). Initial inspiration came from the 'Berlin patient' -an HIV-positive man who developed leukemia and was cured of the infection by allogeneic hematopoietic stem transplantation from a CC chemokine receptor 5 (CCR5) delta32 homozygous donor [5] [6] [7] . This success was followed by the 'Mississippi baby' -an infected newborn who was treated with aggressive combination antiretroviral therapy (cART), beginning 30 h after birth and continuing for 18 months; the absence of rebound viremia over the next 12 months after cART discontinuation [8] raised great excitement about the potential for very early treatment to prevent establishment of persistent viral reservoirs. This hope was dashed when HIV rebounded in the child around 2 years after cART cessation [9] , thereby casting doubt about the potential for early cART alone to achieve a durable drug-free state of HIV remission. In this review, we extend previous suggestions on the potential value of complementing the replication-inhibiting activity of cART regimens with targeted killing of HIV-infected cells [10, 11] . Specifically, we emphasize that the modes of targeted cytotoxic therapy applicable for achieving an HIV cure differ for primary acute versus established chronic infection. For acute infection, relatively short-term treatment with a transiently active modality might provide sufficient complementation of cART to prevent establishment of long-term viral reservoirs, resulting in eradication of virus and infected cells (i.e. a 'sterilizing cure'). For chronic infection, wherein persistent viral reservoirs have already taken hold, a highly durable mode of targeted cell killing is required to provide continuous suppression of persisting replication and ongoing surveillance and destruction of newly activated reservoir cells (i.e. a 'functional cure'). We emphasize that targeted cytotoxic therapy, like a therapeutic vaccine, is conceptually different from cART intensification with additional inhibitors of the virus replication cycle [12] in that it seeks to eliminate cells that are already infected.
TARGETED CYTOTOXIC THERAPIES: MULTIPLE APPROACHES FOR TREATING CANCER
The cancer field has pioneered development of diverse strategies to kill specific target cell types on the basis of their surface overexpression of a molecule(s) that can be targeted by a specific antibody or ligand. These have been extensively reviewed as indicated in the following sections. In considering potential application to HIV infection, it is helpful to distinguish two concepts for targeted cytotoxic therapy.
Transiently active targeted cytotoxic therapy
Various highly potent targeted killing strategies are capable of functioning for only limited duration due to short biological half-life and activity-impairing immune responses. Anticancer efforts have led to diverse approaches in this category, including targeted cytotoxic proteins such as recombinant immunotoxins (RITs) [13] , antibody-drug conjugates [14] , and radiolabeled antibodies [15] , as well as more complex modalities such as oncolytic viruses [16] and targeted nanoparticles delivering cytotoxic components [17] . Also of considerable promise are agents that act indirectly by recruiting host cytotoxic mechanisms, for example, antibodies that promote fragment, crystallizable (FC)-mediated innate effector functions (complement-mediated cytolysis, antibody-dependent cellular cytotoxicity) [18] , as well as bispecific antibodies that redirect T cells to kill selected cell targets [19] . Advances (mostly preclinical) have been made in developing such approaches to treat HIV and other viral infections [20] [21] [22] [23] [24] .
Durably active targeted cytotoxic therapy
Gene therapy strategies are under development for sustained in-vivo delivery of therapeutic proteins for a variety of diseases including cancer and virus infections [25] [26] [27] . Adeno-associated virus (AAV) vectors have shown particular promise, for their ease of administration (intramuscular injection) and ability to elicit sustained high levels of monoclonal antibodies and related proteins in the circulation. Another relevant gene therapy approach involves adoptive transfer of autologous CD8 þ T cells genetically modified ex vivo to express a targeted killing protein construct, such as a cloned T cell receptor (TCR) or a chimeric antigen receptor (CAR). These technologies are demonstrating great promise in the treatment of certain cancers [28] , and have been proposed for use against viruses including HIV [29] .
APPLICATION OF TARGETED CYTOTOXIC THERAPIES FOR TREATING HIV: CONTEXT MATTERS
The distinct obstacles to cure acute versus chronic HIV infection suggest that these conditions will require different modes of targeted cell killing. The selected examples described below illustrate how choices can be guided by basic considerations and some experimental evidence.
Acute HIV infection: transiently active modalities may be suitable HIV-1 latency in humans is established within a few days or weeks after primary infection, raising doubts about whether acute infection can be cured with very early cART alone [9, 30] . A recent study of
KEY POINTS
Targeted killing of HIV-infected cells is a rational complement to cART for curing HIV infection.
Different modalities of targeted cytotoxic therapy are appropriate in efforts to cure acute versus chronic HIV infection.
For acute infection, transiently active modalities are suggested, such as recombinant immunotoxins or antibodies, which act indirectly to promote cytotoxic mechanisms.
For chronic infection, durably active modalities are required, such as genetically modified autologous T cells, to provide continuous suppression of persisting replication and destruction of infected cells activated from latent reservoirs.
Studies in relevant animal models are required to pave the way for clinical trials.
simian immunodeficiency virus (SIV) infection in rhesus macaques modeled this therapeutic challenge: initiation of suppressive cART as early as 3 days postmucosal infection failed to prevent virus emergence upon cessation of a 24-week treatment period [31 && ]. This raised the question that whether complementing cART with targeted cytotoxic therapy, even for a short period, would significantly increase the chances for virus eradiation before reservoir establishment.
Recombinant immunotoxins are fusion proteins generated by linking two components with distinct functions: a targeting moiety (typically a single chain variable fragment [scFv] or a ligand) with high affinity for the surface molecule of interest, and a cytotoxic moiety that potently kills when internalized into the cytosol of the target cell. Ribosomal inactivating proteins from a wide variety of bacterial and plant species have been favored sources of the cytotoxic component [32] ; indeed it has been calculated that a single internalized molecule is sufficient to enzymatically kill a cell. RITs derived from Pseudomonas aeruginosa exotoxin A (PE) have yielded highly favorable early-phase clinical results against certain leukemias [13] . In collaboration with Dr Ira Pastan and co-workers at National Cancer Institute (NCI), National Institutes of Health (NIH) we have developed and characterized PE-based RITs that target HIV-1 gp120 on the surface of the infected cells. Figure 1 shows two anti-HIV RITs with different N-terminal targeting motifs: CD4-PE containing the first two ectodomains of human CD4, and 3B3-PE containing the scFv from a monoclonal antibody (mAb) directed against the CD4 binding site of HIV-1 gp120. Extensive in-vitro analyses (reviewed in [20] ) illustrated the highly potent and specific targeted cytotoxic activities of both RITs against diverse HIV-1 isolates, replicating in relevant human cell types (peripheral blood mononuclear cells [PBMCs] and monocyte-derived macrophages). Importantly, marked synergy was observed between RIT and reverse transcriptase inhibitor activities. When translated to the thy/liv severe combined immunodeficiency (SCID)-hu mouse model [33] , complementation was striking for treatment of acute infection (initiated immediately after challenge). As shown in Fig. 2a , viral load in the thy/liv implant was strongly suppressed by (suboptimal) cART at the end of a 1-month treatment period, but rebounded sharply by 1 month after cART cessation. RIT treatment (CD4-PE or 3B3-PE), which alone had minimal effect during an initial 1-month treatment period (not shown), strikingly enhanced the activity of suboptimal cART, as illustrated by the absence of virus rebound after cessation of treatment (Fig. 2a) . These results highlight the potent complementary action of cART drugs, which block virus replication, and RITs, which kill cells that are already infected. These cooperative activities were much less evident when tested against established HIV-1 infection in this murine model [33] . cART (optimal dose, i.e. sufficient to prevent establishment of infection when administered at the acute stage) suppressed viral load significantly, but not fully, after 1 month of treatment; addition of the 3B3-PE RIT promoted further reduction, but did not eradicate the infection (Fig. 2b) (Fig. 2c) . Taken together, these findings suggest considerable potential value of RITs to complement cART in an effort to cure acute HIV infection; utility against chronic infection seems unlikely. This distinction is further amplified by the fact that current RITs include highly immunogenic foreign components that may be suitable for short-term treatment of acute infection, but not for established infection. The significant recent advances in eliminating B and T-cell epitopes from PE-based RITs [ Anti-HIV/SIV applications are at the forefront of rapidly advancing technologies for gene-based delivery of therapeutic proteins. AAV vectors engendered very high and persisting circulating levels of recombinant neutralizing antibodies that gave substantial protection against SIV [37] and HIV-1 [38, 39] in rhesus macaque and humanized mouse models, respectively. This technology is readily adaptable to the production of proteins for targeted killing of infected cells, including broadly reactive anti-Env (envelope glycoprotein) monoclonal antibodies genetically optimized for Fc-mediated effector functions, as well as bispecific antibodies to redirect T-cell-mediated cytotoxicity. The alternative approach involving adoptive transfer of genetically modified autologous T cells would mimic the cell-mediated immunity sought by therapeutic vaccination [40] or observed in elite controllers [41] , hopefully enabling long-term cessation of cART. Preclinical anti-HIV applications have been described for both alternatives of this approach, i.e. TCRs [42, 43] and CARs [44] [45] [46] [47] [48] [49] [50] [51] . Several factors should be considered in weighing their potential value against HIV. 
Minimization of viral escape
For an scFv-based CAR, a broadly neutralizing antibody is the obvious choice. However, HIV-1 can readily mutate to escape a single antibody despite its broad reactivity [52] ; an scFv-based strategy probably would require (simultaneous) treatment with multiple CARs targeting different epitopes. A CD4-based CAR may circumvent this concern, given the presumed requirement for all viable HIV-1 clinical variants to retain usage of the primary entry receptor. CARs employing CD4 as the targeting motif were tested in clinical studies more than a decade ago [53] [54] [55] , and a subsequent analysis of the peripheral blood samples verified that the CARs persisted and retained expression and proliferative capacity [56] . However, their anti-HIV efficacies in the hosts were modest; this could be attributed to the use of 'first-generation' CAR signaling domains, and possibly also to the susceptibility of the transduced CD8 þ T cells to HIV infection via the CD4-based transgene. Adoptive immunotherapy using cloned TCRs similarly suffers from the well known selection for cytotoxic T lymphocyte (CTL) escape mutants in infected hosts [57] .
Minimization of immunogenicity
Clinical studies in the cancer field have encountered function-impairing antibody responses against scFv-based CARs, primarily against the framework of the murine scFvs currently in use; anti-idiotypic responses against the variable regions have also been noted [58, 59] . Presumably, this issue is minimized with a CD4 CAR, which, apart from the protein linker and junction segments, consists of all-human, nonvariable components. Similarly, human TCR transgenes likely pose minimal risk for eliciting function-impairing immune responses.
Restrictions of activity
A major advantage of CARs is that they are major histocompatibility complex (MHC)-independent and do not require antigen processing, unlike TCRs which recognize peptide-MHC-I complexes. This latter requirement may prove particularly disadvantageous for treating HIV, given the down-modulation of surface MHC-1 in HIV-infected cells [60] .
Variety and kinetic availability of epitopes for T-cell receptors versus chimeric antigen receptors Anti-HIV CARs are limited to targeting Env, the only virus-encoded protein on the infected cell surface. By contrast, TCRs can target a diversity of HIVderived peptide-MHC complexes, and the kinetics of their surface presentation during the virus replication cycle influences CTL susceptibility [57] . The relatively late expression of Env epitopes, closer to the onset of progeny virus release, has been proposed to compromise the effectiveness of CTL against Env relative to Gag -an effect that is amplified by the ability of Gag-specific CTL to recognize antigen delivered by the incoming virion, before viral protein expression [61] . Thus CAR-modified T cells may be at a disadvantage compared to those expressing a cloned TCR against Gag or other viral epitopes expressed earlier in the replication cycle.
Chimeric antigen receptor-mediated susceptibility of transduced CD8
þ T cells to HIV infection It has been suggested that a CD4 CAR might render transduced CD8
þ T cells susceptible to HIV infection [44, 47, 49] , since they endogenously express abundant levels of the CCR5 coreceptor [62] . Thus, additional genetic modifications to the CAR construct may be required to prevent this undesired effect, such as additional sequences (e.g. anti-HIV small interfering RNA) that protect against infection.
Mispairing of T-cell receptor chains A TCR transduced into CD8
þ T cells may be subject to mispairing with the endogenous TCR alpha and beta chains. In addition to reducing surface expression of the transgene, there is the possibility of generating a self-reactive TCR.
An additional concern that may compromise both engineered TCRs and CARs is the emerging notion that follicular CD4 þ T-helper cells (Tfh) in the germinal centers of the peripheral lymph nodes appear to be the major sites of HIV-1 replication during chronic infection. These sites are likely to be sanctuaries protected from the influx of CTL [63] [64] [65] [66] [67] , and their contributions to virus persistence become particularly prominent in the face of a strong CTL pressure as recently shown [68 && ]. This new study of SIV-infected rhesus macaques demonstrated that the low-level productive infection in elite controllers was confined to CD4
þ Tfh cell in the B-cell follicles of the secondary lymphoid tissues, due to elimination of infected CD4 þ T cells from extrafollicular sites by highly potent CTLs, which are excluded from the follicular zone. The authors note the profound implications of the germinal center sanctuary for immunotherapeutic efforts to clear persisting virus and achieve a functional cure. Conversely, the fact that this phenomenon was observed in elite controllers may suggest that potent genetically modified T cells suppress infection sufficiently to achieve this desirable status.
CONCLUSION
As the HIV cure research agenda advances, targeted cytotoxic therapy is likely to play an increasingly prominent role. Our proposed strategies are intended to account for infectious HIV reservoirs in whatever anatomic/cellular compartments they might arise/persist, either by preventing their formation (acute infection; potential 'sterilizing cure') or by providing durable surveillance and killing (chronic infection; potential 'functional cure'). We do not mean to understate the many concerns and questions regarding efficacy, risk, and practicality of the approaches highlighted here. Is the kinetic window of opportunity for curing acute infection so short as to limit the potential beneficiaries to vanishingly small numbers? Will the efficacy of vector-delivered proteins be compromised by their restricted access to sanctuary sites of persisting virus (e.g. central nervous system, testes), and by their potential immunogenicity over the long term involved in maintaining suppression of residual chronic infection? Will genetically modified T cells persist and function for sufficient duration, in all the necessary anatomic sites, to enable long-term freedom from cART? Will scaleability issues preclude implementation of individualized genetic therapies in global regions where they might otherwise provide the maximum benefit? The answers to some of these issues will begin to clarify as results from nonhuman primate studies emerge, and as technologies improve in function and cost. Analogous questions proliferated in the years before development of effective cART, and they should not obstruct the path to finding a cure for HIV infection. . This study showed that in rhesus macaques displaying elite control of SIV infection, the persisting productive replication was confined to CD4 þ Tfh cells in the germinal centers of peripheral lymph nodes, due to their residence in this sanctuary site, which was protected from potent CD8 þ CTLs.
